http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008024284-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3a387adb0bb03da0ec3b96716eda8325 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cbe06463230fc256afc4e018a12ab57b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_714509fac24172a87bb5d79512929201 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202e9e866984fe229f6facc38f1d740 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0e55ad29b925ab328005cee01282c0c7 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4965 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497 |
| filingDate | 2007-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_538372e145f2fce9d8e6cf54ea6a4056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f03c57e91a51b2c05001f77a3aeb4330 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_54faa0dd45dd2ccabb74c86c06368d96 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e98797f646266e310866f1cc237d552c |
| publicationDate | 2008-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2008024284-A3 |
| titleOfInvention | Sulfonylated piperazines as cannabinoid-1 receptor modulators |
| abstract | Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer’s disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson’s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8993577-B2 |
| priorityDate | 2006-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1051.